5-Year Survival Improved With Early Use of Ruxolitinib in Myelofibrosis
An analysis of 5-year data from two large clinical trials provides conclusive support that treatment with ruxolitinib improves long-term survival compared with other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggest that treatment with ruxolitinib should be implemented much earlier in the course of a patient’s disease because it provides a survival advantage over starting treatment with ruxolitinib at a later point in the disease.
Cancer Connect
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology